» Articles » PMID: 36135059

Spinal Lesions As Clinical Manifestations of Plasma Cell Neoplasia

Overview
Journal Curr Oncol
Publisher MDPI
Specialty Oncology
Date 2022 Sep 22
PMID 36135059
Authors
Affiliations
Soon will be listed here.
Abstract

(1) Background: Plasma cell neoplasia can be separated into independent subtypes including multiple myeloma (MM) and solitary plasmacytoma of the bone (SBP). The first clinical signs patients present with are skeletal pain, most commonly involving ribs and vertebrae. (2) Methods: Retrospective analysis of 114 patients (38 female, 76 male) receiving spinal surgery from March 2006 until April 2020. Neurological impairments and surgical instability were the criteria for intervention in this cohort. Analysis was based on demographic data, Spinal Instability Neoplastic Score (SINS), location of the lesion, spinal levels of tumor involvement, surgical treatment, histopathological workup, adjuvant therapy, functional outcome, and overall survival (OS). (3) Results: The following surgical procedures were performed: posterior stabilization only in 9 patients, posterior stabilization and decompression without vertebral body replacement in 56 patients, tumor debulking and decompression only in 8 patients, anterior approach in combined approach without vertebral body replacement and without biopsy and/or without kyphoplasty in 33 patients, 3 patients received biopsies only, and 5 patients received kyphoplasty only. The histopathology diagnoses were MM in 94 cases and SBP in 20 cases. Median OS was 72 months (53.4-90.6 months). Preoperative KPSS was 80% (range 40-100%), the postoperative KPSS was 80% (range 50-100%). (4) Conclusions: Surgery for patients with plasma cell neoplasia is beneficial in case of neurological impairment and spinal instability. Moreover, we were able to show that patients with MM and a low number of spinal levels to be supplied have a better prognosis as well as a younger age at the time of the surgical intervention.

Citing Articles

Percutaneous vertebroplasty/kyphoplasty contributes to the improved outcome in patients with newly diagnosed multiple myeloma: A single center cohort study.

Zhang F, Liu S, Zhou X, Wang W, Jia C, Wang Q J Bone Oncol. 2024; 47:100615.

PMID: 39036812 PMC: 11259919. DOI: 10.1016/j.jbo.2024.100615.


Resection of Thoracic Plasmacytoma and Corpectomy Through the Anterolateral Thoracic Approach: A Case Report.

Del Pino-Camposeco J, Villanueva-Castro E, Deustua-Hernandez D, Canela-Calderon O, Martinez-de la Maza E, Arriada-Mendicoa J Cureus. 2024; 15(12):e50627.

PMID: 38226126 PMC: 10789388. DOI: 10.7759/cureus.50627.


A Case Report of Plasmacytoma in a 28-Year-Old Patient: Bridging the Age Gap in a Rare Presentation.

Kizhakkayil Tency N, Camarena J, Roy A, Pradeep M Cureus. 2023; 15(10):e47671.

PMID: 38022027 PMC: 10672403. DOI: 10.7759/cureus.47671.

References
1.
Wang Y, Li H, Liu C, Chen C, Yan J . Solitary Plasmacytoma of Bone of the Spine: Results From Surveillance, Epidemiology, and End Results (SEER) Registry. Spine (Phila Pa 1976). 2018; 44(2):E117-E125. DOI: 10.1097/BRS.0000000000002777. View

2.
Richardson P, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D . Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma. Blood. 2005; 106(9):2977-81. DOI: 10.1182/blood-2005-02-0691. View

3.
Ludwig H, Durie B, Bolejack V, Turesson I, Kyle R, Blade J . Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group. Blood. 2008; 111(8):4039-47. PMC: 4259800. DOI: 10.1182/blood-2007-03-081018. View

4.
Wallington M, Mendis S, Premawardhana U, Sanders P . Local control and survival in spinal cord compression from lymphoma and myeloma. Radiother Oncol. 1997; 42(1):43-7. DOI: 10.1016/s0167-8140(96)01858-0. View

5.
Kumar S, Mikhael J, Buadi F, Dingli D, Dispenzieri A, Fonseca R . Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines. Mayo Clin Proc. 2009; 84(12):1095-110. PMC: 2787395. DOI: 10.4065/mcp.2009.0603. View